GSA Capital Partners LLP Raises Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

GSA Capital Partners LLP raised its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 138.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 608,585 shares of the company’s stock after purchasing an additional 353,384 shares during the quarter. GSA Capital Partners LLP owned 0.86% of Zentalis Pharmaceuticals worth $2,240,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Decheng Capital LLC boosted its position in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after buying an additional 970,859 shares during the last quarter. XTX Topco Ltd lifted its stake in Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after acquiring an additional 167,854 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares during the period. Finally, Algert Global LLC purchased a new position in shares of Zentalis Pharmaceuticals during the second quarter worth $78,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZNTL shares. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research report on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.25.

Zentalis Pharmaceuticals Trading Up 1.8 %

NASDAQ ZNTL opened at $4.03 on Tuesday. The stock has a market capitalization of $286.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.74. The stock has a 50-day moving average of $3.38 and a 200 day moving average of $5.59. Zentalis Pharmaceuticals, Inc. has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the previous year, the firm posted ($1.85) earnings per share. Equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.02 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.